For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Raloxifene hydrochloride - Breast cancer - chemoprevention
PAD Profile : Raloxifene hydrochloride - Breast cancer - chemoprevention
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a formulary status for tamoxifen, anastrozole and raloxifene for chemoprevention in women at moderate or high risk of developing breast cancer for a duration of 5 years.
A BLUE (with specialist initiation) with 1 month prescribing by the specialist team following discussions with the patient about the risks and benefits of treatment.
Raloxifene (off-label for this indication) can be used:
- Postmenopausal in those with a uterus and have severe osteoporosis or do not wish to take anastrozole or tamoxifen if no past history or increased risk of thromboembolic disease
On occasion a patient may need time to consider treatment and may in those circumstances request that their GP prescribe. The GP will then need to consider if they have all the information from the specialist team in order to accept full clinical responsibility for prescribing for that patient.